Year None202420232022202120202019 1/23/2024 Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock 1/22/2024 Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3
1/22/2024 Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH